Previous 10 | Next 10 |
CRISPR Therapeutics AG (CRSP) is expected to report $-1.98 for Q3 2023
2023-11-06 18:57:21 ET More on Vertex Pharmaceuticals Vertex Pharmaceuticals Incorporated 2023 Q3 - Results - Earnings Call Presentation Vertex Pharmaceuticals Deserves Its Monopoly Premium Indeed A Total Return Superstar: Vertex Pharmaceuticals Vertex Pharma...
2023-11-06 17:23:14 ET More on CRISPR Therapeutics CRISPR Therapeutics: Positive Exa-Cel AdCom Opens Door For Historic Approval Risk And Reward: Evaluating Crispr's Exa-Cel For Sickle Cell Crispr: Upcoming Catalysts, Plenty Of Cash And Strong Partnerships Make It A B...
-Advisory Committee meeting for exagamglogene autotemcel (exa-cel) for the treatment of severe sickle cell disease (SCD) completed October 31, 2023; exa-cel assigned Prescription Drug User Fee Act (PDUFA) target action date of December 8, 2023 for SCD- -Exa-cel assigned PDUFA target act...
2023-11-03 15:23:43 ET More on XBI and IBB Biopharma Bounce-Back: From Policy Pains To Profitable Plains IBB: The Illness Of Idiosyncratic Risk Jefferies is bullish on XBI at around $70 for year-end and first quarter 2024 returns Citi turns cautious on pharma...
2023-11-03 09:56:47 ET Gene therapy stocks have been a bright spot in the market this week. For instance, gene correction specialist CRISPR Therapeutics (NASDAQ: CRSP) has so far gained 19.6% through the first four days of trading this week, according to data provided by S&P G...
2023-11-03 08:05:00 ET On Oct. 31, Vertex Pharmaceuticals (NASDAQ: VRTX) and its collaborator CRISPR Therapeutics (NASDAQ: CRSP) met with regulators at the Food and Drug Administration (FDA) in a high-stakes meeting about commercializing the pair's gene therapy for sickle ce...
2023-11-03 05:00:00 ET With all of the stocks out there, it's sometimes difficult to choose just a few to add to your portfolio at any given time. So what should you look for? It's always important to consider a company's track record and/or future prospects, valuation, and potential cataly...
2023-11-02 05:30:00 ET CRISPR Therapeutics (NASDAQ: CRSP) has reached a very important chapter in its growth story. The gene-editing specialist doesn't have products on the market right now, but that could change in just a few weeks. The U.S. Food and Drug Administration (FDA) is se...
2023-11-01 13:45:35 ET Summary CRISPR Therapeutics AG and Vertex Pharmaceuticals are one step closer to gaining approval for their CRISPR/Cas9 gene editing therapy for Sickle Cell Disease and beta thalassemia. An FDA Advisory Committee raised a few concerns about the safety of the...
News, Short Squeeze, Breakout and More Instantly...
CRISPR Therapeutics AG Company Name:
CRSP Stock Symbol:
NASDAQ Market:
CRISPR Therapeutics AG Website:
2024-07-17 10:10:00 ET July 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compan...